{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:36:26Z","timestamp":1793118986822,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T00:00:00Z","timestamp":1568332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI Grant","award":["JP17K16845"],"award-info":[{"award-number":["JP17K16845"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10147-019-01540-9","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T14:02:55Z","timestamp":1568383375000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The efficacy and toxicity of 4-day chemotherapy with methotrexate, etoposide and actinomycin D in patients with choriocarcinoma and high-risk gestational trophoblastic neoplasia"],"prefix":"10.1007","volume":"25","author":[{"given":"Shizuka","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0517-5091","authenticated-orcid":false,"given":"Eiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiro","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Kikkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,13]]},"reference":[{"issue":"4","key":"1540_CR1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.ejca.2012.09.015","volume":"49","author":"C Lybol","year":"2013","unstructured":"Lybol C, Thomas CM, Blanken EA et al (2013) Comparing cisplatin-based combination chemotherapy with EMA\/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur J Cancer 49(4):860\u2013867. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2012.09.015","journal-title":"Eur J Cancer"},{"issue":"2","key":"1540_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1525-1438.2007.00999.x","volume":"18","author":"WG Lu","year":"2008","unstructured":"Lu WG, Ye F, Shen YM et al (2008) EMA-CO chemotherapy for high-risk gestational trophoblastic neoplasia: a clinical analysis of 54 patients. Int J Gynecol Cancer 18(2):357\u2013362. \nhttps:\/\/doi.org\/10.1111\/j.1525-1438.2007.00999.x","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"1540_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.1997.15.7.2636","volume":"15","author":"M Bower","year":"1997","unstructured":"Bower M, Newlands ES, Holden L et al (1997) EMA\/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. J Clin Oncol 15(7):2636\u20132643. \nhttps:\/\/doi.org\/10.1200\/JCO.1997.15.7.2636","journal-title":"J Clin Oncol"},{"issue":"2","key":"1540_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/gyno.1998.5161","volume":"71","author":"SJ Kim","year":"1998","unstructured":"Kim SJ, Bae SN, Kim JH et al (1998) Risk factors for the prediction of treatment failure in gestational trophoblastic tumors treated with EMA\/CO regimen. Gynecol Oncol 71(2):247\u2013253. \nhttps:\/\/doi.org\/10.1006\/gyno.1998.5161","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1540_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ygyno.2003.08.028","volume":"91","author":"PF Escobar","year":"2003","unstructured":"Escobar PF, Lurain JR, Singh DK et al (2003) Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. Gynecol Oncol 91(3):552\u2013557","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1540_CR6","first-page":"113","volume":"83","author":"JT Soper","year":"1994","unstructured":"Soper JT, Evans AC, Clarke-Pearson DL et al (1994) Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin\/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. Obstet Gynecol 83(1):113\u2013117","journal-title":"Obstet Gynecol"},{"issue":"6","key":"1540_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1471-0528.1991.tb10369.x","volume":"98","author":"ES Newlands","year":"1991","unstructured":"Newlands ES, Bagshawe KD, Begent RH et al (1991) Results with the EMA\/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 98(6):550\u2013557","journal-title":"Br J Obstet Gynaecol"},{"issue":"1","key":"1540_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1006\/gyno.2000.5813","volume":"78","author":"H Matsui","year":"2000","unstructured":"Matsui H, Suzuka K, Iitsuka Y et al (2000) Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors. Gynecol Oncol 78(1):28\u201331. \nhttps:\/\/doi.org\/10.1006\/gyno.2000.5813","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1540_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/gyno.1996.4534","volume":"64","author":"V Soto-Wright","year":"1997","unstructured":"Soto-Wright V, Goldstein DP, Bernstein MR et al (1997) The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Gynecol Oncol 64(1):156\u2013159. \nhttps:\/\/doi.org\/10.1006\/gyno.1996.4534","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1540_CR10","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1054\/bjoc.2000.1176","volume":"82","author":"LS Dobson","year":"2000","unstructured":"Dobson LS, Lorigan PC, Coleman RE et al (2000) Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease. Br J Cancer 82(9):1547\u20131552. \nhttps:\/\/doi.org\/10.1054\/bjoc.2000.1176","journal-title":"Br J Cancer"},{"issue":"3","key":"1540_CR11","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1525-1438.2006.00606.x","volume":"16","author":"T Turan","year":"2006","unstructured":"Turan T, Karacay O, Tulunay G et al (2006) Results with EMA\/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer 16(3):1432\u20131438. \nhttps:\/\/doi.org\/10.1111\/j.1525-1438.2006.00606.x","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1540_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0020-7292(02)00063-2","volume":"77","author":"Committee FO","year":"2002","unstructured":"Committee FO (2002) FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet 77(3):285\u2013287","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"1540_CR13","first-page":"545","volume":"49","author":"LA Cole","year":"2004","unstructured":"Cole LA, Sutton JM (2004) Selecting an appropriate hCG test for managing gestational trophoblastic disease and cancer. J Reprod Med 49(7):545\u2013553","journal-title":"J Reprod Med"},{"issue":"5","key":"1540_CR14","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3892\/mco.2016.1011","volume":"5","author":"E Yamamoto","year":"2016","unstructured":"Yamamoto E, Niimi K, Fujikake K et al (2016) High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: a case report and literature review. Mol Clin Oncol 5(5):660\u2013664. \nhttps:\/\/doi.org\/10.3892\/mco.2016.1011","journal-title":"Mol Clin Oncol"},{"issue":"6","key":"1540_CR15","first-page":"438","volume":"49","author":"H Matsui","year":"2004","unstructured":"Matsui H, Iitsuka Y, Suzuka K et al (2004) Salvage chemotherapy for high-risk gestational trophoblastic tumor. J Reprod Med 49(6):438\u2013442","journal-title":"J Reprod Med"},{"issue":"4","key":"1540_CR16","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2000.18.4.854","volume":"18","author":"ES Newlands","year":"2000","unstructured":"Newlands ES, Mulholland PJ, Holden L et al (2000) Etoposide and cisplatin\/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA\/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 18(4):854\u2013859. \nhttps:\/\/doi.org\/10.1200\/JCO.2000.18.4.854","journal-title":"J Clin Oncol"},{"issue":"9","key":"1540_CR17","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/annonc\/mdn181","volume":"19","author":"J Wang","year":"2008","unstructured":"Wang J, Short D, Sebire NJ et al (2008) Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel\/cisplatin alternating with paclitaxel\/etoposide (TP\/TE). Ann Oncol 19(9):1578\u20131583. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdn181","journal-title":"Ann Oncol"},{"key":"1540_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.gynor.2014.04.001","volume":"9","author":"E Yamamoto","year":"2014","unstructured":"Yamamoto E, Niimi K, Shinjo K et al (2014) Identification of causative pregnancy of gestational trophoblastic neoplasia diagnosed during pregnancy by short tandem repeat analysis. Gynecol Oncol Case Rep 9:3\u20136. \nhttps:\/\/doi.org\/10.1016\/j.gynor.2014.04.001","journal-title":"Gynecol Oncol Case Rep"},{"issue":"4","key":"1540_CR19","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/endo.137.4.8625917","volume":"137","author":"S Birken","year":"1996","unstructured":"Birken S, Maydelman Y, Gawinowicz MA et al (1996) Isolation and characterization of human pituitary chorionic gonadotropin. Endocrinology 137(4):1402\u20131411. \nhttps:\/\/doi.org\/10.1210\/endo.137.4.8625917","journal-title":"Endocrinology"},{"issue":"1","key":"1540_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1067\/mob.2002.124284","volume":"187","author":"GD Braunstein","year":"2002","unstructured":"Braunstein GD (2002) False-positive serum human chorionic gonadotropin results: causes, characteristics, and recognition. Am J Obstet Gynecol 187(1):217\u2013224","journal-title":"Am J Obstet Gynecol"},{"issue":"22","key":"1540_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1056\/NEJM197311292892202","volume":"289","author":"GL Warne","year":"1973","unstructured":"Warne GL, Fairley KF, Hobbs JB et al (1973) Cyclophosphamide-induced ovarian failure. N Engl J Med 289(22):1159\u20131162. \nhttps:\/\/doi.org\/10.1056\/NEJM197311292892202","journal-title":"N Engl J Med"},{"issue":"2","key":"1540_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ygyno.2004.02.018","volume":"93","author":"S Goto","year":"2004","unstructured":"Goto S, Ino K, Mitsui T et al (2004) Survival rates of patients with choriocarcinoma treated with chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. Gynecol Oncol 93(2):529\u2013535. \nhttps:\/\/doi.org\/10.1016\/j.ygyno.2004.02.018","journal-title":"Gynecol Oncol"},{"issue":"6411","key":"1540_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/bmj.288.6411.103","volume":"288","author":"GJ Rustin","year":"1984","unstructured":"Rustin GJ, Booth M, Dent J et al (1984) Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J (Clin Res Ed) 288(6411):103\u2013106","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"1540_CR24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1046\/j.1471-0528.2003.02419.x","volume":"110","author":"CA Lok","year":"2003","unstructured":"Lok CA, van der Houwen C, ten Kate-Booij MJ et al (2003) Pregnancy after EMA\/CO for gestational trophoblastic disease: a report from The Netherlands. BJOG 110(6):560\u2013566","journal-title":"BJOG"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01540-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01540-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T23:50:51Z","timestamp":1599868251000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01540-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,13]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01540-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,13]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No potential conflict of interest relevant to this article was reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}